KIRKLAND, Wash., Sept. 17 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the “Company”) has entered into a collaborative research agreement with physician scientists at Cleveland Clinic of Cleveland, Ohio. The goal of the collaboration is to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte’s proprietary compounds.
CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart. The goal of this therapy is to increase the number of stem cells delivered to a damaged organ, thereby markedly increasing organ healing and functional restoration. The Company’s first product in development, CCG-TH30, is designed to send autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack. In preclinical models, CCG-TH30 has been shown to increase the retention of stem cells up to as much as 80% compared to conventional methods, which achieve only up to about 7%. Importantly, CellCyte’s product can be delivered intravenously through the patients’ circulatory system without an invasive procedure.
Sathyamangla Prasad Ph.D., and Wilson Tang, M.D., of Cleveland Clinic, who are both accomplished scientists in the field of cardiac biology, will analyze heart tissue samples of heart failure patients for the presence of surface receptors that are hypothesized to play an important role in the interaction of stem cells with the heart. These studies may provide valuable novel information that will increase our understanding of cardiac regeneration and may support the discovery and development of novel stem cell therapeutics for the heart. Work on the project is expected to start in October 2007. Dr. Prasad is the primary investigator.
Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2006, there were 3.1 million outpatient visits to Cleveland Clinic, from every state and from more than 80 countries. There were more than 53,000 hospital admissions to Cleveland Clinic. Cleveland Clinic’s Web site address is http://www.clevelandclinic.org.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products.
For further information see: http://www.cellcyte.com. Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV. Contact North America: Investor Relations Toll Free Telephone: 877.688.5050 Contact Europe: Investor Relations Telephone: (+49) 69.7593.8451
Safe Harbor Statement
This news release contains “forward-looking statements”, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this news release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Except for the historical information presented herein, matters discussed in this news release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words as “estimate,” “anticipate,” “believe,” “plan” or “expect” or similar statements are forward-looking statements. Risks and uncertainties for the company include, but are not limited to, the risks associated with the closing of the closing of the share exchange agreement and the development and funding of the company consequent thereon, as well as the risks shown in the company’s most recent annual report on form 10-ksb and on form 10-qsb and from time-to-time in other publicly available information regarding the company. Other risks include risks associated with the regulatory approval process, competitive companies, future capital requirements and the company’s ability and level of support for its research and development activities. There can be no assurance that the company’s development efforts will succeed and the company will ultimately achieve commercial success.
These forward-looking statements are made as of the date of this news release, and the company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the company’s periodic reports filed from time-to-time with the United States Securities and Exchange Commission. This news release has been prepared by management of the company who take full responsibility for its contents. Each of the NASD, the SEC and the OTCBB neither approves nor disapproves of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
CellCyte Genetics Corporation
CONTACT: North America Investor Relations, 1-877-688-5050, Europe InvestorRelations, (+49) 69.7593.8451, both of CellCyte Genetics Corporation
